These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 9095206)

  • 61. Phase II trial of PALA in combination with 5-fluorouracil in advanced pancreatic cancer.
    Rosvold E; Schilder R; Walczak J; DiFino SM; Flynn PJ; Banerjee TK; Heim WJ; Engstrom PF; Ozols RF; O'Dwyer PJ
    Cancer Chemother Pharmacol; 1992; 29(4):305-8. PubMed ID: 1537077
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Antitumor activity of N-(phosphonacetyl)-L-aspartic acid, a transition-state inhibitor of aspartate transcarbamylase.
    Johnson RK; Inouye T; Goldin A; Stark GR
    Cancer Res; 1976 Aug; 36(8):2720-5. PubMed ID: 1064466
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Phase I trial of combination therapy of cancer with N-phosphonacetyl-L-aspartic acid and dipyridamole.
    Markman M; Chan TC; Cleary S; Howell SB
    Cancer Chemother Pharmacol; 1987; 19(1):80-3. PubMed ID: 3815730
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Antitumor activity of the weekly intravenous push schedule of 5-fluoro-2'-deoxyuridine +/- N-phosphonacetyl-L-aspartate in mice bearing advanced colon carcinoma 26.
    van Laar JA; Durrani FA; Rustum YM
    Cancer Res; 1993 Apr; 53(7):1560-4. PubMed ID: 8453623
    [TBL] [Abstract][Full Text] [Related]  

  • 65. A phase I, II study of high-dose 5-fluorouracil and high-dose leucovorin with low-dose phosphonacetyl-L-aspartic acid in patients with advanced malignancies.
    Ardalan B; Sridhar KS; Benedetto P; Richman S; Waldman S; Morrell L; Feun L; Savaraj N; Fodor M; Livingstone A
    Cancer; 1991 Sep; 68(6):1242-6. PubMed ID: 1873776
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Biochemical modulation of 5-fluorouracil by PALA.
    O'Dwyer PJ
    Cancer Invest; 1990; 8(2):261-2. PubMed ID: 2400945
    [No Abstract]   [Full Text] [Related]  

  • 67. Potentiation by guanine nucleosides of the growth-inhibitory effects of adenosine analogs on L1210 and sarcoma 180 cells in culture.
    Grindey GB; Lowe JK; Divekar AY; Hakala MT
    Cancer Res; 1976 Feb; 36(2 Pt 1):379-83. PubMed ID: 944090
    [TBL] [Abstract][Full Text] [Related]  

  • 68. High-dose 5-fluorouracil plus low dose methotrexate plus or minus low-dose PALA in advanced colorectal cancer: a randomised phase II-III trial of the EORTC Gastrointestinal Group.
    Wils J; Blijham GH; Wagener T; De Greve J; Jansen RL; Kok TC; Nortier JW; Bleiberg H; Couvreur ML; Genicot B; Baron B;
    Eur J Cancer; 2003 Feb; 39(3):346-52. PubMed ID: 12565987
    [TBL] [Abstract][Full Text] [Related]  

  • 69. 6-Methylmercaptopurine riboside is a potent and selective inhibitor of nerve growth factor-activated protein kinase N.
    Volonté C; Greene LA
    J Neurochem; 1992 Feb; 58(2):700-8. PubMed ID: 1309569
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Biophysical aspects of the integrated combination of cytostatic drugs with radiotherapy. Part 2: Dose-effect relationships and 31P NMR spectroscopy of L 1210 cells (monolayers) and 9L glioma cells (monolayers and tumor spheroids) treated with activated isophosphamide, adriamycin, epirubicin and 6 MeV electrons.
    Ulmer W
    Strahlenther Onkol; 1991 Aug; 167(8):484-93. PubMed ID: 1887366
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Effect of docetaxel on the therapeutic ratio of fractionated radiotherapy in vivo.
    Mason KA; Kishi K; Hunter N; Buchmiller L; Akimoto T; Komaki R; Milas L
    Clin Cancer Res; 1999 Dec; 5(12):4191-8. PubMed ID: 10632360
    [TBL] [Abstract][Full Text] [Related]  

  • 72. The proteasome inhibitor PS-341 in cancer therapy.
    Teicher BA; Ara G; Herbst R; Palombella VJ; Adams J
    Clin Cancer Res; 1999 Sep; 5(9):2638-45. PubMed ID: 10499643
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Influence of 6-aminonicotinamide (6AN) on Leishmania promastigotes evaluated by metabolomics: Beyond the pentose phosphate pathway.
    Almugadam SH; Trentini A; Maritati M; Contini C; Rugna G; Bellini T; Manfrinato MC; Dallocchio F; Hanau S
    Chem Biol Interact; 2018 Oct; 294():167-177. PubMed ID: 30170107
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Effects of Fluosol-DA and oxygen breathing on adriamycin antitumor activity and cardiac toxicity in mice.
    Teicher BA; Holden SA; Crawford JM
    Cancer; 1988 Jun; 61(11):2196-201. PubMed ID: 3365649
    [TBL] [Abstract][Full Text] [Related]  

  • 75. In vivo 31P NMR study of the metabolism of murine mammary 16/C adenocarcinoma and its response to chemotherapy, x-radiation, and hyperthermia.
    Evanochko WT; Ng TC; Lilly MB; Lawson AJ; Corbett TH; Durant JR; Glickson JD
    Proc Natl Acad Sci U S A; 1983 Jan; 80(2):334-8. PubMed ID: 6572896
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Marked radiosensitization of cells in culture to X ray by 5-chlorodeoxycytidine coadministered with tetrahydrouridine, and inhibitors of pyrimidine biosynthesis.
    Perez LM; Mekras JA; Briggle TV; Greer S
    Int J Radiat Oncol Biol Phys; 1984 Aug; 10(8):1453-8. PubMed ID: 6236189
    [TBL] [Abstract][Full Text] [Related]  

  • 77. A phase II multi-institutional trial of low-dose N-(phosphonacetyl)-L-aspartate and high-dose 5-fluorouracil as a short-term infusion in the treatment of adenocarcinoma of the pancreas. A Southwest Oncology Group study.
    Morrell LM; Bach A; Richman SP; Goodman P; Fleming TR; MacDonald JS
    Cancer; 1991 Jan; 67(2):363-6. PubMed ID: 1985731
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Dose-dependent inhibition of aspartate carbamoyltransferase in peripheral blood mononuclear cells in patients receiving N-(phosphonacetyl)-L-aspartate.
    Grem JL; McAtee N; Drake JC; Steinberg S; Allegra CJ
    Adv Exp Med Biol; 1993; 339():119-23. PubMed ID: 8178710
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Effects of combinations of 7beta-hydroxycholesterol and anticancer drugs or ionizing radiation on the proliferation of cultured tumor cells.
    Hyun JW; Holl V; Weltin D; Dufour P; Luu B; Bischoff P
    Anticancer Res; 2002; 22(2A):943-8. PubMed ID: 12014676
    [TBL] [Abstract][Full Text] [Related]  

  • 80. [Biochemical modulation of 5-FU by thymidine and N-phosphoacetyl-L-aspartate: the relation between 5-FU incorporation into RNA and its cytocidal effect].
    Akazawa S; Kumai R; Shimizu K; Ayusawa D; Seno T; Yoshida S
    Gan To Kagaku Ryoho; 1986 Apr; 13(4 Pt 1):990-5. PubMed ID: 3963863
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.